导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -1.74% | 2800/4773 |
| 近一周 | -1.80% | 3430/5467 |
| 近一月 | -5.34% | 2335/5421 |
| 近一季 | -7.70% | 2439/5238 |
| 近半年 | -1.98% | 2162/4931 |
| 近一年 | 0.25% | 2540/4400 |
| 近两年 | 43.56% | 1714/2954 |
| 近三年 | 26.84% | 1204/2253 |
| 成立以来 | 61.34% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.63% 3319/4961 |
11.69% 2306/5312 |
- - |
- - |
| 2025 | 19.46% 2217/4813 |
-0.93% 2475/3635 |
2.29% 1680/4076 |
17.83% 2423/4524 |
0.05% 2261/4813 |
| 2024 | 15.85% 869/3463 |
2.89% 675/2808 |
-1.02% 896/3014 |
16.67% 1388/3129 |
-2.49% 2109/3463 |
| 2023 | -7.63% 933/2656 |
4.52% 932/2280 |
-3.55% 830/2385 |
-2.17% 633/2515 |
-6.33% 1726/2655 |
| 2022 | -18.86% 767/2207 |
-13.71% 823/1919 |
6.87% 587/2016 |
-13.37% 893/2113 |
1.57% 1216/2208 |
| 2021 | 1.37% 678/1822 |
-2.25% 606/1255 |
5.89% 787/1330 |
-3.93% 670/1466 |
1.94% 745/1822 |
| 2020 | 38.73% 349/1250 |
-8.31% 598/1028 |
15.01% 521/1067 |
15.04% 240/1164 |
14.37% 283/1184 |
| 2019 | - - |
- - |
- - |
- - |
7.96% 375/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4796 | 32.41% |
| 港股通药 | 0.9109 | 32.37% |
| 万家中证港股通创新药ETF | 1.6293 | 32.25% |
| 景顺长城中证港股通创新药ETF | 1.6918 | 32.17% |
| 天弘恒生沪深港创新药精选50ETF | 0.8599 | 32.08% |
| 港股医疗 | 0.9703 | 31.90% |
| 港医疗 | 0.9212 | 31.83% |
| 港股通医疗ETF工银 | 0.9798 | 31.81% |
| 港股通医疗ETF华宝 | 0.9918 | 31.64% |
| 万家中证港股通创新药ETF发起式联接A | 1.4193 | 31.06% |
| 永赢沪深300ETF发起联接C VS. 长安沪深300非周期A(740101) |